- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03652662
RESP-FIT: Technology-Enhanced Self-Management in COPD (RESP-FIT)
March 4, 2021 updated by: Medical University of South Carolina
30 adults, aged 40 and older with mild to moderate COPD, will be recruited for this study.
Participants must be willing to continually wear a FitBit activity monitor, have access to a smartphone or Wi-Fi/Data-enabled iPad, and be willing to complete respiratory muscle strength training exercises as well as reports on their smartphone at least 5 times per week for a 6-week period.
Participants will be given a bluetooth inhaler device and a training app (RESP-FIT).
This application will collect inhaler data and allows patients to self-report their daily symptoms.
The goal of this study is to test whether use of the personalized inhaler device with the app strengthens lung function, promotes physical activity, and improves disease symptom self-management in persons with COPD.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
RESP-FIT.
The RESP-FIT program is a 6-week respiratory muscle strength training intervention adapted from previous respiratory muscle strength training (RMST) training regimens, consisting of 1) five training days/week using combined inspiratory and expiratory muscle training, consisting of breathing in and out against a combine inspiratory and expiratory muscle strength trainer (IMST/EMST), 2) individualized, progress-based text message training reminders and prompts related to timing and intensification calibration, and 3) use of a Fitbit for remote monitoring of physical activity and hours slept at night.
Similar to other muscle strength training programs, exercises are done at regular intervals during the week (5 breaths, 5 times a day, 5 days a week; the participant will receive graphical illustration of RESP-FIT training frequency and intensity achieved, and based on their training regimen, will be prompted and/or reinforced via SMS text messaging).
As the use of an accelerometer or remote tracking device alone may affect physical activity, a control group will receive only the Fitbit.
This study proposes to assess the feasibility and initial efficacy of RMST by obtaining estimates of variability in fatigue secondary to dyspnea, using a technologically-enhanced RESP-FIT intervention.
Our overarching hypothesis is that a training regimen consisting of RMST along with technology-enhanced symptom-tracking will decrease dyspnea, dyspnea-related activity avoidance, and fatigue.
Additionally, this application proposes to further develop Smartphone Airway Monitoring System (SAMS) which currently integrates EMA probe questions covering COPD symptoms and preventive care use with the new functions, use in an adult population with COPD, video captured training technique and logging of RMST training sessions.
Up to thirty adults with COPD (age over 40) will complete the study and use the SAMS app for 6 weeks in the natural environment.
We will evaluate the acceptability, feasibility, adherence, and performance of RESP-FIT + SAMS through quantitative methods to further optimize the app and related study procedures for the next phase of testing (i.e., large scale efficacy RCT).
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 40 years of age or older; and
- Able to read and write English; and
- Diagnosed with mild to moderate COPD (PFT values: FEV1/FVC <0.7 and FEV1% predicted < 50% - within the past 6 months); and
- Dyspnea score of greater than "2" on the Modified Medical Research Council (MMRC) questionnaire.
Exclusion Criteria:
• Pregnant female or less than 1 year post-partum; or
- Diagnosed cognitive deficit or observed lack of understanding during the informed consent process; or
- Mobility impairment; or
- Lack of 3g WiFi access in place of residence; or
- Unwillingness to wear physical activity tracker daily, follow protocol, and/ or attend study visits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RESP-FIT Intervention
Intervention: IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS) |
Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
Other Names:
|
Active Comparator: RESP-FIT Comparator
Active Comparator: Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS) |
Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intervention Feasibility (Number of Participants Who Adhered to Treatment)
Time Frame: through study completion, average of 6 weeks
|
Feasibility of intervention was measured by the number of participants who adhered to treatment and completed the trial (from baseline to final visit follow-up).
Treatment acceptability was measured by the Mobile Application Rating Scale.
The Mobile Application Rating Scale asks the participant to report the appropriateness of the app for his/her target audience ranging from little or no (1) to very high level of the acceptability measure (5).
|
through study completion, average of 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Self-efficacy
Time Frame: baseline, 6 weeks
|
Change in self-efficacy (measured with the PROMIS Self-Efficacy Scale).
This measures the individual's confidence in his/her ability to successfully perform specific tasks or behaviors related to one's health, with 0 being "not at all confident" to 10 being "totally confident."
The PROMIS adult Self-Efficacy item banks assess self-reported current level of confidence in managing chronic conditions, including confidence in managing daily activities, managing emotions, managing medications and treatments, managing social interactions and managing symptoms.
|
baseline, 6 weeks
|
Change in Fatigue
Time Frame: baseline, 6 weeks
|
Change in fatigue (measured with the PROMIS v1.0 Fatigue Scale).
The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles.
Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities.
A higher PROMIS T-score represents more of the concept being measured.
For negatively-worded concepts like fatigue, a T-score of 60 is one SD worse than average.
|
baseline, 6 weeks
|
Dyspnea
Time Frame: baseline, 6 weeks
|
Change in difficulty breathing (measured with the PROMIS v1.0 Dyspnea).
Participant can select from 5 items evaluating how shortness of breath over the past 7 days affected ability to do various activities (Getting dressed, walking stairs, household chores, or walking fast pace) ranging from "I did not do this," "no difficulty," "a little difficulty," "some difficulty," and "much difficulty."
A score of 50 is the average for the general population with a standard deviation of 10 as calibration testing was performed on a large sample of the general population.
The dyspnea instruments were calibrated on a sample of adults with COPD, so a score of 50 is the average for people with COPD.
For the adult PROMIS Dyspnea Severity 10a short form, a raw score of 10 converts to a T-score of 48.8 with a standard error (SE) of 2.0, for an average dyspnea rating.
The T-score can range from 29.7-76.7.
A higher score represents more dyspnea being measured.
|
baseline, 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Sarah Miller, PhD, RN, Medical University of South Carolina
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 18, 2018
Primary Completion (Actual)
January 13, 2020
Study Completion (Actual)
January 13, 2020
Study Registration Dates
First Submitted
June 26, 2018
First Submitted That Met QC Criteria
August 28, 2018
First Posted (Actual)
August 29, 2018
Study Record Updates
Last Update Posted (Actual)
March 30, 2021
Last Update Submitted That Met QC Criteria
March 4, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- Pro00071706
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
As a condition of this National Institutes of Nursing Research (NINR) award, de-identified patient data will be shared by the researchers with the NINR and stored electronically on an NIH password protected secure server (https://cdrns.nih.gov/).
The purpose of sharing this information is to build a NINR repository of data using Common Data Elements (CDE) for future research purposes among the general scientific community and for public health benefit.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Not yet recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
University Hospital, BrestRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Baylor Research InstituteNot yet recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
Clinical Trials on RESP-FIT
-
Strados Labs, Inc.WithdrawnChronic Obstructive Pulmonary Disease (COPD)United States
-
Strados Labs, Inc.WithdrawnCOVID-19 | Asthma | RSV Infection | Pediatric Respiratory DiseasesUnited States
-
Strados Labs, Inc.Completed
-
Strados Labs, Inc.RecruitingAsthma | Asthma in Children | Wheezing | Pediatric AsthmaUnited States
-
Whisper.aiSan Jose State UniversityRecruitingHearing LossUnited States
-
University of California, IrvineCompletedCardiovascular Diseases | Cardiovascular Risk FactorUnited States
-
University of Wisconsin, MadisonCompletedOverweightUnited States
-
Oregon Health and Science UniversityRecruitingAmyotrophic Lateral Sclerosis | Muscular Dystrophies | Spinal Cord Injuries | Multiple System Atrophy | Parkinson's Disease and Parkinsonism | Brain Tumor Adult | Locked-in Syndrome | Brainstem StrokeUnited States
-
University of Texas Southwestern Medical CenterCancer Prevention Research Institute of TexasCompletedColorectal Cancer
-
University of Illinois at ChicagoNational Institute on Aging (NIA)CompletedOsteoarthritis | Overweight and ObesityUnited States